VisionHealth GmbH, corporate

VisionHealth GmbH,

23.11.2021 - 14:03:47

VisionHealth's Kata Clinical app to support sterna biologicals' clinical Phase IIa asthma trial

Not only therapy but also clinical study outcomes are highly dependent on properly applied drugs including inhaler usage and dosing. Incorrect inhalation results in underdosing of drugs, leading to data scattering and possibly invalid data. Kata(R) Clinical trains the patient and controls the therapeutic inhalation, thus delivering trustworthy and consistent results.


About VisionHealth VisionHealth GmbH is a pioneer of digital therapy support for respiratory diseases. In cooperation with research institutions and selected industry partners, medical experts and IT experts, VisionHealth develops innovative and unique digital health solutions enabling sustainable improvements to existing standard therapies for patients with chronic lung diseases like asthma and COPD. The Munich-based private company, was founded in 2017 by inhalation therapy specialists. Investors include business angels and private investors with many years of industry expertise, particularly in inhalation therapies.

About Kata(R) Kata(R) is a VisionHealth proprietary platform based on artificial intelligence to support inhalation therapy. The aim of the Kata(R) app for patients is to optimize the drug inhalation therapy of chronic lung diseases through digital support. Clinical evidence shows that patients frequently fail to correctly perform their necessary and regular inhalation due to a lack of therapy adherence or knowledge. As a result, the prescribed medications are not adequately delivered to the respiratory airways. A multitude of different devices for drug inhalation increases the training effort for physicians and patients and makes therapy monitoring almost impossible. This issue affects around 250 million people worldwide suffering from chronic lung diseases to whom Kata(R) could bring urgently needed relief. Kata(R) is a proprietary platform application providing a completely novel and unique combination of artificial intelligence and computer animation - it is one of the first digital applications to have received medical device certification.

A modified Kata(R) app for clinical trials (Kata( Clinical) combines data and patient management to enhance the participants' experience and improve study outcomes at the same time. Based on the customized adaptation to the specific needs of a study, data collection and management can be conducted more efficiently and are less error-prone due to

About sterna biologicals sterna biologicals GmbH & Co. KG is an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and ulcerative colitis. By targeting transcription factors that play a central role in regulating inflammatory mechanisms, the Company's proprietary DNAzyme-based drug candidates can intervene with key inflammatory processes to address related diseases more effectively. So far, sterna has advanced four programs into Phase 2 development. For more information, please visit

Contact Dr. Sabine Haeussermann | CEO | +49 151 701 865 89 | VisionHealth GmbH | Landsberger Str. 72 | 80339 M?nchen

Media Contact MC Services AG Katja Arnold / Dr. Brigitte Keller +49 89 210228

References[1] Press VG et al. J Gen Intern Med. 2011; 26:635-42.[2] The Inhaler Error Steering Committee. Respir Med. 2013; 107:37-46.[3] Price DB et al. J Allergy Clin Immunol Pract. 2017; 5:1071-1081.e9.[4] Molimard M et al. Eur Resp J. 2017; 49:1601794;[5] Lindh A et al. Nursing Open 2019; 6:1519-1527;

23.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at